SCHEMBL7220147

SCHEMBL7220147

Fc1ccc2c(c1)C(CCN1CC=C(c3c[nH]c4cc(Cl)ccc34)CC1)CN2

nearest known ligand 0.57

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 2/20 0.51
SLC6A4 P31645 8/20 0.49
DRD2 P14416 8/20 0.49
ADRA1D P25100 1/20 0.49
HTR1B P28222 1/20 0.49
ADRA1A P35348 1/20 0.49
ADRA1B P35368 1/20 0.49
HTR1A P08908 10/20 0.49
HTR7 P34969 6/20 0.49
HTR6 P50406 6/20 0.49
OPRM1 P35372 1/20 0.45
OPRK1 P41145 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5139395 0.89 HTR1D (0.53) HTR1DSLC6A4DRD2HTR1AHTR7
SCHEMBL6680408 0.89 HTR1D (0.53) HTR1DSLC6A4DRD2HTR1AHTR7
SCHEMBL7213744 0.83 DRD2 (0.56) HTR1DSLC6A4DRD2HTR1AHTR7
SCHEMBL7220243 0.82 HTR1D (0.52) HTR1DSLC6A4DRD2ADRA1DHTR1B
SCHEMBL7215934 0.81 HTR1D (0.50) HTR1DSLC6A4DRD2ADRA1DHTR1B
SCHEMBL7220921 0.80 HTR1D (0.52) HTR1DSLC6A4DRD2ADRA1DHTR1B
SCHEMBL7219780 0.78 HTR1D (0.51) HTR1DSLC6A4DRD2ADRA1DHTR1B
SCHEMBL7213712 0.78 HTR1D (0.48) HTR1DSLC6A4DRD2ADRA1DHTR1B
SCHEMBL7213620 0.77 HTR1D (0.56) HTR1DSLC6A4DRD2HTR1AHTR7
SCHEMBL7214358 0.76 HTR1D (0.48) HTR1DSLC6A4DRD2ADRA1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6552044-B2 Dopamine receptors H. LUNDBECK A/S (DK) 2003-04-22 US disclosed
US-6352988-B2 HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION H. LUNDBECK A/S (DK) 2002-03-05 US disclosed
US-20010021777-A1 Indane or dihydroindole derivatives H. LUNDBECK A/S (DK) 2001-09-13 US disclosed
US-20010020095-A1 Indane or dihydroindole derivatives H. LUNDBECK A/S (DK) 2001-09-06 US disclosed
US-6262087-B1 HAVE HIGH AFFINITY FOR D4 RECEPTORS; USEFUL IN THE TREATMENT OF CERTAIN PSYCHIATRIC AND NEUROLOGIC DISORDERS, INCLUDING PSYCHOSIS, DEPRESSION AND ANXIETY. H. LUNDBECK A/S (DK) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010020095-A1 Indane or dihydroindole derivatives HTR4, GPR4, GPR174 HTR1D 4/4885SLC6A4 40/4885DRD2 14/4885
US-20010021777-A1 Indane or dihydroindole derivatives HTR4, GPR4, GPR174 HTR1D 4/4885SLC6A4 40/4885DRD2 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.